On May 9, 2023 Neurix SA reported that CYTEA|BIO SAS has selected our BlastomaBrain platform to perform its pre-clinical validation in anticipation of its IND filing with the FDA (Press release, CYTEA BIO, MAY 9, 2023, View Source [SID1234631236]). CYTEA is developing a novel immunotherapy approach to address an urgent unmet medical need for glioblastoma patients. Glioblastoma models developed by Neurix using patient-derived glioblastoma samples offer the opportunity to test personalised therapies for the disease.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very proud of the fact that our platform has been selected for such an exciting new therapy that offers to transform the lives of patients, and provide an alternative to animal testing for an FDA IND dossier" said Neurix’s CEO Nikolay Zhukovsky.

CYTEA|BIO’s CEO, Alan Cookson said: CYTEA|BIO relishes this opportunity to employ the BlastomaBrainTM platform to evaluate the safety and efficacy of our PinTM immunotherapy treatment for GBM. Pre-clinical platforms that offer more predictive outcomes to animal studies are an important innovation for the pharmaceutical industry.